Food and Drug Administration Amendments Act

Food and Drug Administration Amendments Act
Name	Food and Drug Administration Amendments Act
Long title	An Act to amend the Federal Food, Drug, and Cosmetic Act
Enacted by	109th United States Congress
Effective date	2007
Public law	Public Law 110–85
Introduced in	United States House of Representatives
Signed by	George W. Bush
Signed date	September 27, 2007

Food and Drug Administration Amendments Act The Food and Drug Administration Amendments Act is a United States statute enacted in 2007 that expanded the regulatory authorities and resources of the United States Food and Drug Administration. It amended provisions of the Federal Food, Drug, and Cosmetic Act and created new mandates affecting pharmaceutical safety, postmarketing surveillance, clinical trial registration, and labeling requirements. The law followed high-profile safety controversies and interacted with contemporaneous statutes and regulatory developments at agencies such as the Centers for Disease Control and Prevention, National Institutes of Health, and United States Department of Health and Human Services.

Background and Legislative History

Legislative impetus arose after safety concerns associated with drugs and devices implicated during the administrations of Bill Clinton and George W. Bush, and following investigations by committees led by figures such as Charles Grassley and Ted Kennedy. Congressional hearings in the 109th United States Congress featured testimony from officials from the Food and Drug Administration, executives from firms including Pfizer and GlaxoSmithKline, and academics from institutions like Johns Hopkins University and Harvard Medical School. The bill moved through the United States House Committee on Energy and Commerce and the United States Senate Committee on Health, Education, Labor, and Pensions before final passage and signature by President George W. Bush. The statute built on prior legislation including the Prescription Drug User Fee Act and responded to reports from oversight bodies such as the Government Accountability Office.

Key Provisions and Authorities

The Act authorized expanded powers for the Food and Drug Administration including enhanced inspection authority, product labeling mandates, and the ability to require postmarket studies. It created new fee authorities and mechanisms similar to the Medical Device User Fee and Modernization Act to support regulatory review. The statute established frameworks for adverse event reporting involving industry actors such as Johnson & Johnson, Merck, AstraZeneca, and Eli Lilly, and clarified coordination with federal entities including the Office of the Inspector General (United States Department of Health and Human Services), the Department of Justice, and the Federal Trade Commission for enforcement matters.

Drug Safety and Postmarketing Surveillance

A central focus was strengthening postmarketing surveillance through mandates for mandatory risk assessments, expanded adverse event database authority, and increased inspection capabilities. The Act empowered the FDA to require postmarketing studies from sponsors such as Novartis, Bristol-Myers Squibb, and Sanofi and enhanced the Agency’s ability to require safety labeling changes. It improved use of data sources including the FDA Adverse Event Reporting System, claims datasets from insurers like UnitedHealthcare and Anthem, and electronic health records initiatives linked with Centers for Medicare & Medicaid Services. The law also anticipated collaborations with academic consortia such as Duke University and Stanford University for pharmacoepidemiologic research.

Labeling, Risk Evaluation, and Mitigation Strategies (REMS)

The statute formalized new tools for risk control including the authority to require Risk Evaluation and Mitigation Strategies (REMS) for selected drugs and biologics. REMS provisions allowed conditions such as restricted distribution, prescriber certification, and patient medication guides; these interact with stakeholders like American Medical Association, American Pharmacists Association, and pharmacy chains including Walgreens and CVS Health. The Act’s REMS authority has been applied to products produced by manufacturers including Celgene and Biogen and coordinated with programs administered by the Centers for Disease Control and Prevention for vaccine safety.

Clinical Trial Registry and Data Transparency

The law expanded requirements for registration and results reporting in clinical trial registries, building on the Food and Drug Administration Modernization Act of 1997 and complementing initiatives such as ClinicalTrials.gov operated by the National Library of Medicine. Sponsors including academic centers such as University of California, San Francisco and industry sponsors like Amgen were required to submit trial protocols and outcomes, improving access for oversight bodies such as the Institutional Review Boards and researchers at institutions like Yale University and Columbia University. These transparency provisions intersected with litigation involving consumer advocates like Public Citizen and with scientific journals including The New England Journal of Medicine and The Lancet.

Implementation, Enforcement, and Funding

Implementation relied on appropriations and user fees authorized under the Act, coordinated through budget processes involving the United States Congress and executive branch offices including the Office of Management and Budget. Enforcement actions invoked civil remedies and coordination with Department of Justice for criminal referrals; notable enforcement cases implicated firms such as Pfizer and GlaxoSmithKline in other contexts. The Act funded staffing increases at FDA centers including the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research, and supported information systems modernization with partners such as National Institutes of Health.

Impact, Criticism, and Subsequent Amendments

The statute materially changed FDA’s regulatory toolkit, affecting approvals, postmarket oversight, and data transparency; commentators from Brookings Institution, Kaiser Family Foundation, and The Pew Charitable Trusts have analyzed its effects. Criticism centered on resource sufficiency, industry influence highlighted by watchdogs like Public Citizen and hearings in the United States Congress, and operational challenges reported by FDA leadership including Margaret Hamburg. Subsequent legislation and policy shifts—such as reauthorizations of user fee acts and amendments arising during the 111th United States Congress and later sessions—further modified the statutory landscape and guided ongoing debates involving stakeholders like Pharmaceutical Research and Manufacturers of America and patient advocacy groups including the National Organization for Rare Disorders.

Category:United States federal health legislation